TY - JOUR
T1 - ABO blood group and effectiveness of tocilizumab in clinical response to COVID-19
T2 - A single center, retrospective study
AU - Nasution, Izza Aulia Rizqika
AU - Andrajati, Retnosari
AU - Syafhan, Nadia Farhanah
AU - Imaniar, Rania
N1 - Funding Information:
None to declare.
Publisher Copyright:
© 2023 by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0. To view a copy of this license, visit https://www.creativecommons.org/licenses/by-nc-nd/4.0/
PY - 2023
Y1 - 2023
N2 - As an anticytokine therapy, tocilizumab has been recommended for the management therapy in patients with severe and serious COVID-19 cases. The association between the severity of COVID-19 and blood groups has been the subject of prior research. Therefore, it is important to analyze the relationship between blood types and the effectiveness of tocilizumab (TCZ) therapy in COVID-19 patients. This research involved 68 patients diagnosed with severe and critical COVID-19 receiving Tocilizumab (TCZ) therapy at Universitas Indonesia Hospital. Blood type O was associated with a significantly improvement in CRP levels (P=0.014) and has better favorable outcomes compared to other blood type in terms of WHO Clinical Progression Scale (OR: 1.254, 95% CI: 0.457-3.443; P=0.797), length of stay (OR: 5,333, 95% CI: 0.495-3,734; P=0.614), and improvement in CRP levels (OR: 5,333, 95% CI: 1.385-20,541; P=0.014).
AB - As an anticytokine therapy, tocilizumab has been recommended for the management therapy in patients with severe and serious COVID-19 cases. The association between the severity of COVID-19 and blood groups has been the subject of prior research. Therefore, it is important to analyze the relationship between blood types and the effectiveness of tocilizumab (TCZ) therapy in COVID-19 patients. This research involved 68 patients diagnosed with severe and critical COVID-19 receiving Tocilizumab (TCZ) therapy at Universitas Indonesia Hospital. Blood type O was associated with a significantly improvement in CRP levels (P=0.014) and has better favorable outcomes compared to other blood type in terms of WHO Clinical Progression Scale (OR: 1.254, 95% CI: 0.457-3.443; P=0.797), length of stay (OR: 5,333, 95% CI: 0.495-3,734; P=0.614), and improvement in CRP levels (OR: 5,333, 95% CI: 1.385-20,541; P=0.014).
KW - Blood Types
KW - COVID-19
KW - Interleukin-6 Inhibitors
KW - SARS-CoV-2
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=85169463452&partnerID=8YFLogxK
U2 - 10.29090/psa.2023.03.22.331
DO - 10.29090/psa.2023.03.22.331
M3 - Article
AN - SCOPUS:85169463452
SN - 2586-8195
VL - 50
SP - 204
EP - 210
JO - Pharmaceutical Sciences Asia
JF - Pharmaceutical Sciences Asia
IS - 3
ER -